

SUREmAb™

**Monoclonal Antibody Development,
the Way it's Meant to Be**

Join a Legacy of Success

SUREmAb™ is built on the
power of our Selexis®
SUREtechnology™ Platform

25+

Years of CLD Experience

190+

Drug Candidates

10+

Commercialized mABs

Simple, secure, and streamlined from cell line development (CLD) to drug substance release

SUREmAb™ preemptively navigates technical hurdles for exceptional performance, delivering high titers (up to 18 g/L) with a streamlined, lower-cost workflow. Thanks to this preset offer, your simple mAb development is made SURE, while accelerating timelines and maximizing ROI.



Efficient processes
for high titers and
exceptional yield



Drug substance
release in as little
as 11 months




Transfection to
high-performing
RCB in as little as
9 weeks



Innovation with
alleviation of royalties
when you manufacture
with KBI Biopharma

SUREmAb™: Research Cell Bank (RCB) Generation, Simplified



11 Months

Real Data, Real Confidence

See how SUREmAb™ delivers simple, secure, and streamlined mAb development, with performance data that empowers you with high yields, scalable processes, and consistent quality.

High titer and Scalable Processes





Fig. 1: SUREmAb™ technology provides high performing RCB cell lines with a scalable production process. (A) Cell viability and density and (B) titer of a model mAb RCB at three different scales; ambr15, 3L, and 200L bioreactors, using the CHO-optimized medium, CELLiST™ Basal CHO MX, are shown in corresponding colors.



Minimize Risk with Consistent Quality

Fig. 2: SUREmAb™ model mAb RCB delivers consistent product quality across key attributes: (A) purity, (B) charge variants, and (C) N-glycan profiles across scales (Ambr® 15, 3L, 200L), providing the quality consistency required for regulatory confidence and commercial manufacturing.

Ready to Simplify Your mAb Development?

Our SUREmAb™ experts handle the development challenges so you can focus on the cures. Our streamlined platform delivers reliable results through proven processes and expert guidance.



Speak with our specialists about simplifying your development process.

Please note: The SUREmAb™ offer does not apply to mAb-based biosimilar projects or for any IgG shape-derived proteins that are different from an intact IgG format - including bsAbs, Fc fusions, and IgG fragments - as well as other protein classes outside of IgGs. Timeline estimates are subject to open manufacturing capacity and may vary by project.

